
CLAIMS






1. Use of a compound of Formula (I), or a pharmaceutically acceptable salt thereof, in the preparation of a medicament for ameliorating or treating a viral infection, wherein the compound of Formula (I) has the structure:



(I)

wherein:

B^{1A} is selected from the group consisting of:





, 
, 
, 
and 
, wherein R^{G2} is an unsubstituted C_{1-6} alkyl;

R^{3A} is halo or OH;

R^{4A} is OH or halo;


R^{a1} and R^{a2} are independently hydrogen or deuterium;


R^{A} is hydrogen or deuterium;

R^{1A} is selected from the group consisting of hydrogen 
, 
and 
;

R^{2A} is hydrogen, halo, $-(CH_2)_{1-6}$halogen or $-(CH_2)_{1-6}N_3$;

R^{5A} is selected from the group consisting of hydrogen, an unsubstituted C_{1-6} alkyl, an unsubstituted C_{2-6} alkenyl and an unsubstituted C_{2-6} alkynyl;

R^{6A} and R^{7A} are independently selected from the group consisting of absent, hydrogen and  ; or

R^{6A} is  and R^{7A} is absent or hydrogen;

R^{8A} is an optionally substituted phenyl or an optionally substituted naphthyl;

R^{9A} is an optionally substituted N-linked α-amino acid or an optionally substituted N-linked α-amino acid ester derivative;

R^{10A} and R^{11A} are independently an optionally substituted N-linked α-amino acid or an optionally substituted N-linked α-amino acid ester derivative;

R^{12A} and R^{13A} are independently absent or hydrogen;

R^{14A} is O^- or OH;

R^{22A} and R^{23A} are each hydrogen;

R^{24A} is selected from the group consisting of hydrogen, an optionally substituted C_{1-24} alkyl and substituted $-O-C_{1-24}$ alkyl;

m is 0 or 1;

s is 0, 1, 2 or 3; and

Z^{1A}, Z^{2A}, Z^{3A} and Z^{4A} are each O;

wherein the viral infection is caused by a virus selected from the group consisting of MERS-CoV, SARS-CoV, Venezuelan equine encephalitis virus, Chikungunya virus and a coronavirus; and

when a group is substituted, the group is substituted with one or more substituents selected from the group consisting of alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, heteroaryl, heterocyclyl, aryl(alkyl), heteroaryl(alkyl), (heterocyclyl)alkyl, hydroxy, alkoxy, acyl, cyano, halogen, thiocarbonyl, O-carbamyl, N-carbamyl, O-thiocarbamyl, N-thiocarbamyl,

C-amido, N-amido, S-sulfonamido, N-sulfonamido, C-carboxy, O-carboxy, isocyanato, thiocyanato, isothiocyanato, nitro, azido, silyl, sulfenyl, sulfinyl, sulfonyl, haloalkyl, haloalkoxy, trihalomethanesulfonyl, trihalomethanesulfonamido, an amino, a mono-substituted amino group and a di-substituted amino group; and

wherein an –N–linked α-amino acid ester derivative refers to an α-amino acid in which a main-chain carboxylic acid group has been converted to an ester group.

2. The use of Claim 1, wherein the virus is MERS-CoV.

3. The use of Claim 1, wherein the virus is SARS-CoV.

4. The use of Claim 1, wherein the virus is a Venezuelan equine encephalitis virus.

5. The use of Claim 1, wherein the virus is Chikungunya virus

6. The use of Claim 1, wherein the virus is a coronavirus.

7. The use of any one of Claims 1-6, wherein R^{2A} is hydrogen.

8. The use of any one of Claims 1-6, wherein R^{2A} is halo.

9. The use of Claim 8, wherein the halo is fluoro.

10. The use of any one of Claims 1-6, wherein R^{2A} is $-(CH_2)_{1-6}$ halogen.

11. The use of Claim 10, wherein R^{2A} is $-(CH_2)_{1-6}F$.

12. The use of Claim 10, wherein R^{2A} is $-(CH_2)_{1-6}Cl$.

13. The use of any one of Claims 1-6, wherein R^{2A} is $-(CH_2)_{1-6}N_3$.

14. The use of any one of Claims 1-13, wherein R^{4A} is OH.

15. The use of any one of Claims 1-13, wherein R^{4A} is halo.

16. The use of Claim 15, wherein the halo is F.

17. The use of Claim 15, wherein the halo is Cl.


18. The use of any one of Claims 1-17, wherein R^{5A} is hydrogen.


19. The use of any one of Claims 1-17, wherein R^{5A} is an unsubstituted C_{1-6} alkyl.


20. The use of any one of Claims 1-17, wherein R^{5A} is an unsubstituted C_{2-6} alkenyl.

21. The use of any one of Claims 1-17, wherein R^{5A} is an unsubstituted C_{2-6} alkynyl.


22. The use of any one of Claims 1-21, wherein R^{1A} is hydrogen.


23. The use of any one of Claims 1-21, wherein R^{1A} is  .

24. The use of Claim 23, wherein R^{6A} is  , R^{7A} is absent or hydrogen; and m is 0.

25. The use of Claim 23, wherein R^{6A} is  , R^{7A} is absent or hydrogen; and m is 1.

26. The use of Claim 23, wherein R^{6A} and R^{7A} are independently absent or hydrogen.


27. The use of Claim 23, wherein R^{6A} and R^{7A} are independently  .

28. The use of any one of Claims 1-21, wherein R^{1A} is  .

29. The use of Claim 28, wherein R^{8A} is an optionally substituted phenyl.








30. The use of Claim 28, wherein R^{8A} is an optionally substituted naphthyl.


31. The use of any one of Claims 28-30, wherein R^{9A} is an optionally substituted N-linked amino acid or an optionally substituted N-linked amino acid ester derivative.

32. The use of any one of Claims 28-30, wherein R^{9A} is  wherein R^{33A} is selected from the group consisting of hydrogen, an optionally substituted C_{1-6} alkyl, an optionally substituted C_{3-6} cycloalkyl, an optionally substituted aryl, an optionally substituted aryl(C_{1-6} alkyl) and an optionally substituted haloalkyl; R^{34A} is selected from the group consisting of hydrogen, an optionally substituted C_{1-6} alkyl, an optionally substituted C_{1-6} haloalkyl, an optionally substituted C_{3-6} cycloalkyl, an optionally substituted C_6 aryl, an optionally substituted C_{10} aryl and an optionally substituted aryl(C_{1-6} alkyl); and R^{35A} is hydrogen

or an optionally substituted C_{1-4} alkyl; or R^{34A} and R^{35A} are taken together to form an optionally substituted C_{3-6} cycloalkyl.


33. The use of Claim 32, wherein R^{9A} is selected from the group consisting of







and

.










34. The use of any one of Claims 1-21, wherein R^{1A} is .

35. The use of Claim 34, wherein R^{10A} and R^{11A} are independently an optionally substituted N-linked amino acid or an optionally substituted N-linked amino acid ester derivative.



36. The use of Claim 34, wherein R^{10A} and R^{11A} are independently wherein R^{36A} is selected from the group consisting of hydrogen, an optionally substituted C_{1-6} alkyl, an optionally substituted C_{3-6} cycloalkyl, an optionally substituted aryl, an optionally substituted aryl(C_{1-6} alkyl) and an optionally substituted haloalkyl; R^{37A} is selected from the group consisting of hydrogen, an optionally substituted C_{1-6} alkyl, an optionally substituted C_{1-6} haloalkyl, an optionally substituted C_{3-6} cycloalkyl, an optionally substituted C_6 aryl, an optionally substituted C_{10} aryl and an optionally substituted aryl(C_{1-6} alkyl); and R^{38A} is hydrogen or an optionally substituted C_{1-4} alkyl; or R^{37A} and R^{38A} are taken together to form an optionally substituted C_{3-6} cycloalkyl.

37. The use of Claim 36, wherein R^{10A} and R^{11A} are independently selected from the group consisting of  ,  ,  ,  ,  ,  and  .

38. The use of any one of Claims 1-37, wherein R^{3A} is halo.

39. The use of Claim 38, wherein the halo is fluoro.

40. The use of Claim 38, wherein the halo is chloro.


41. The use of any one of Claims 1-37, wherein R^{3A} is OH.


42. The use of any one of Claims 1-41, wherein R^{A} is hydrogen.


43. The use of any one of Claims 1-41, wherein R^{A} is deuterium.


44. The use of any one of Claims 1-43, wherein R^{a1} and R^{a2} are both hydrogen.


45. The use of any one of Claims 1-43, wherein R^{a1} and R^{a2} are both deuterium.

46. The use of any one of Claims 1-45, wherein B^{1A} is  .

47. The use of any one of Claims 1-45, wherein B^{1A} is  .

48. The use of any one of Claims 1-45, wherein B^{1A} is  .

49. The use of any one of Claims 1-45, wherein B^{1A} is  .

50. The use of any one of Claims 1-45, wherein B^{1A} is  .

51. The use of Claim 1, wherein:

















R^{2A} is selected from the group consisting of hydrogen, F and $-CH_2F$;








R^{3A} is OH or F;

R^{4A} is selected from the group consisting of OH, Cl and F; and













R^{5A} is methyl or ethynyl.
















52. The use of any one of Claims 1-6, 22-37 and 46-50, wherein the compound of Formula (I) is selected from the group consisting of:




,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,


,

,

,

,

,

and

, or a pharmaceutically acceptable salt of any of the foregoing.

53. The use of Claim 1, wherein the compound is selected from the group consisting of:








,

,

,

,

,

,

,

,

,

,

,

,














,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

and , or a pharmaceutically acceptable salt of any of the foregoing.











54. The use of Claim 1, wherein the compound is selected from the group consisting of:



,

,

,

,

,

,


,

,

,

,

,

,

,

,

,

,

,

,


,

,



,

,

,

,

,

,

,

,

,

,




,




,




,




,




,



,












,




,

- 454 -



,

,

,

,

,

,

,

,




,




,




,




,




,













,











,


























,


,

,

,

,

,

,

,

,

,

,


,

,

,

,

,

,

and

, or a pharmaceutically acceptable salt of any of the foregoing.













55. The use of Claim 1, wherein the compound is selected from the group consisting of:


,

,

,

,

,

,

,

,

,

,

,


,

,

,

,

,

,

,

,

,

,

,

,


,


,



,

,

,

,

,

,

,

,

,

,

,

,

,

,



,


and


, or a pharmaceutically acceptable salt of any of the foregoing.